Home

Premiér rozmazlovat přebytek 5 year overall survival in Snížení Pomlouvat Provinění

Frontiers | Incremental Value of Radiomics in 5-Year Overall Survival  Prediction for Stage II–III Rectal Cancer
Frontiers | Incremental Value of Radiomics in 5-Year Overall Survival Prediction for Stage II–III Rectal Cancer

Five-year survival analysis of surgically resected gastric cancer cases in  Japan: a retrospective analysis of more than 100,000 patients from the  nationwide registry of the Japanese Gastric Cancer Association (2001–2007)  | SpringerLink
Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007) | SpringerLink

VENCLEXTA® (venetoclax tablets) | Additional Follow-up Data for CLL/SLL
VENCLEXTA® (venetoclax tablets) | Additional Follow-up Data for CLL/SLL

Overall survival curve by treatment method. The 5-year overall survival...  | Download Scientific Diagram
Overall survival curve by treatment method. The 5-year overall survival... | Download Scientific Diagram

Assessment of 5-year overall survival in bladder cancer patients with  incidental prostate cancer identified at radical cystoprostatectomy |  SpringerLink
Assessment of 5-year overall survival in bladder cancer patients with incidental prostate cancer identified at radical cystoprostatectomy | SpringerLink

PDF] Long-Term (5 Year) Overall Survival in Zuma-1, the Pivotal Study of  Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B-Cell  Lymphoma (LBCL) by Caron A. Jacobson, Frederick L. Locke, Armin Ghobadi,
PDF] Long-Term (5 Year) Overall Survival in Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B-Cell Lymphoma (LBCL) by Caron A. Jacobson, Frederick L. Locke, Armin Ghobadi,

Study shows survival benefits of smoking cessation after lung cancer  diagnosis
Study shows survival benefits of smoking cessation after lung cancer diagnosis

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in  human small cell lung Cancer (SCLC) | Journal for ImmunoTherapy of Cancer |  Full Text
Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC) | Journal for ImmunoTherapy of Cancer | Full Text

A nomogram to predict overall survival for biliary tract cancer | CMAR
A nomogram to predict overall survival for biliary tract cancer | CMAR

5-year overall survival almost doubled with pembrolizumab for metastatic  NSCLC patients with a PD-L1 TPS ≥ 50% and without EGFR/ALK alterations -  BJMO
5-year overall survival almost doubled with pembrolizumab for metastatic NSCLC patients with a PD-L1 TPS ≥ 50% and without EGFR/ALK alterations - BJMO

Therapeutic method for early-stage second primary non-small lung cancer:  analysis of a population-based database | BMC Cancer | Full Text
Therapeutic method for early-stage second primary non-small lung cancer: analysis of a population-based database | BMC Cancer | Full Text

5-year overall survival almost doubled with pembrolizumab for metastatic  NSCLC patients with a PD-L1 TPS ≥ 50% and without EGFR/ALK alterations -  BJMO
5-year overall survival almost doubled with pembrolizumab for metastatic NSCLC patients with a PD-L1 TPS ≥ 50% and without EGFR/ALK alterations - BJMO

Clinical Significance of INHBA Gene Expression in Patients with Gastric  Cancer who Receive Curative Resection Followed by Adjuvant S-1 Chemotherapy  | In Vivo
Clinical Significance of INHBA Gene Expression in Patients with Gastric Cancer who Receive Curative Resection Followed by Adjuvant S-1 Chemotherapy | In Vivo

OA08.03 The 5-year Survival Rate of Postoperative Non-small Cell Lung  Cancer Patients with Two Different Follow-up Patterns - Journal of Thoracic  Oncology
OA08.03 The 5-year Survival Rate of Postoperative Non-small Cell Lung Cancer Patients with Two Different Follow-up Patterns - Journal of Thoracic Oncology

Overall Survival Data: Primary & Exploratory 5-Year Landmark Analysis -  ALECENSA® (alectinib)
Overall Survival Data: Primary & Exploratory 5-Year Landmark Analysis - ALECENSA® (alectinib)

IMFINZI® (durvalumab) Efficacy & Clinical Trials for NSCLC
IMFINZI® (durvalumab) Efficacy & Clinical Trials for NSCLC

Efficacy for Newly Diagnosed Glioblastoma (GBM) | Optune®
Efficacy for Newly Diagnosed Glioblastoma (GBM) | Optune®

5-year overall survival in patients with lung cancer eligible or ineligible  for screening according to US Preventive Services Task Force criteria: a  prospective, observational cohort study - The Lancet Oncology
5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology

SciELO - Brasil - SURVIVAL OF PATIENTS WITH COLORECTAL CANCER IN A CANCER  CENTER SURVIVAL OF PATIENTS WITH COLORECTAL CANCER IN A CANCER CENTER
SciELO - Brasil - SURVIVAL OF PATIENTS WITH COLORECTAL CANCER IN A CANCER CENTER SURVIVAL OF PATIENTS WITH COLORECTAL CANCER IN A CANCER CENTER

5-year Overall Survival Rates by Stage at Presentation | Download  Scientific Diagram
5-year Overall Survival Rates by Stage at Presentation | Download Scientific Diagram

Long-term survival and stage I breast cancer subtypes - ScienceDirect
Long-term survival and stage I breast cancer subtypes - ScienceDirect

Avelumab in patients with previously treated metastatic Merkel cell  carcinoma (JAVELIN Merkel 200): updated overall survival data after >5  years of follow-up - ESMO Open
Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up - ESMO Open

Predictive model for the 5-year survival status of osteosarcoma patients  based on the SEER database and XGBoost algorithm | Scientific Reports
Predictive model for the 5-year survival status of osteosarcoma patients based on the SEER database and XGBoost algorithm | Scientific Reports

Cancers | Free Full-Text | Trends in Overall Survival and Treatment  Patterns in Two Large Population-Based Cohorts of Patients with Breast and  Colorectal Cancer | HTML
Cancers | Free Full-Text | Trends in Overall Survival and Treatment Patterns in Two Large Population-Based Cohorts of Patients with Breast and Colorectal Cancer | HTML

A prognostic nomogram for overall survival in male breast cancer with  histology of infiltrating duct carcinoma after surgery [PeerJ]
A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery [PeerJ]